IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.

Shu Jin, Tao Zhu, Yi Huang, Xu Qin, Ruixia Guo, Huiling Liu, Hongwei Zhao, Lijing Zhu, Xia Wang, Xiaohong Xu, Wenjun Cheng, Jie Tang, Qi-Zhou Zhu, Xiaojun Chen, Ruifang An, Jun Gao, Guiling Li, Zhiye Zhang, Hui Zhou, Qi ZhouJournal of Clinical Oncology 2025 · DOI

Abstract

5565 Background: IBI354 is an antibody-drug conjugate consisting of trastuzumab (anti-HER2 antibody) conjugated to a topoisomerase I inhibitor. It has showed manageable safety and encouraging efficacy in patients (pts) with advanced gynecologic cancers (including ovarian cancers [OC], Shu et al, abstract No. 720MO at 2024 ESMO annual meeting). Here, we present the updated safety and efficacy in OC. Methods: Eligible OC pts with HER2 alteration (IHC 1+, 2+, 3+ and/or ISH+ and/or NGS confirmed mutation or amplification) who failed or were intolerant to standard treatment were enrolled from China and Australia. Pts received IBI354 at 2−12 mg/kg every three weeks (Q3W) or Q2W. Primary endpoint was safety. Secondary endpoints were objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) per RECIST v1.1. Results: As of November 12, 2024, 92 pts were enrolled (median age, 58.0 years; Asian, 95.7%; White, 4.3%; ECOG PS 1, 73.9%; IHC 1+, 65.2%; IHC 2+, 29.3%). The median follow-up time was 11.0 months (range: 8.0−19.0). Median treatment duration was 24.1 (range: 3.1−60.3) weeks with 21 (22.8%) pts still on treatment. Treatment-related adverse events (TRAEs) occurred in 79 (85.9%) pts with grade ≥ 3 TRAEs in 27 (29.3%) pts. The most common TRAEs were anemia (51.1%), white blood cell count decreased (45.7%), neutrophil count decreased (40.2%), and nausea (35.9%). Serious TRAEs occurred in 10 (10.9%) pts. Interstitial lung disease or pneumonitis was observed in 1 (1.1%) pt, which was grade 2 and not related to IBI354 considered by the investigator. TRAEs led to dose reduction in 2 (2.2%) pts. No TRAEs led to treatment discontinuation or death. For efficacy-evaluable pts (who had at least 1 post-baseline tumor assessment) dosed at 12 mg/kg Q3W (n = 40), confirmed ORR and DCR reached 55.0% (95% CI: 38.5−70.7) and 90.0% (95% CI: 76.3−97.2), respectively. In 22 pts with confirmed response in 12 mg/kg Q3W dose group, the median DoR was not reached with events occurred in 6 (27.3%) pts, and 9-month DoR rate of 58.1% (24.2−81.2). The median PFS was 7.1 months (95% CI: 5.2−not reached) with events occurred in 21 (51.2%) pts. The median overall survival (OS) was not reached with events occurred in 12 (29.3%) pts, and the 9 month OS rate was 70.7% (95% CI: 54.3−82.2). For the pts with HER2 IHC 1+ OC dosed at 12 mg/kg Q3W (accounting for 67.5% [27/40] of efficacy-evaluable pts at 12 mg/kg Q3W), ORR and DCR reached 55.6% (95% CI: 35.3−74.5) and 88.9% (70.8−97.6), respectively. Conclusions: IBI354 was well tolerated with a manageable safety profile and showed promising efficacy in pts with locally advanced unresectable or metastatic OC, especially in pts with HER2 lower expression. Clinical trial information: NCT05636215 .
BibTeX
@article{jin2025ibi,
  author = {Shu Jin and Tao Zhu and Yi Huang and Xu Qin and Ruixia Guo and Huiling Liu and Hongwei Zhao and Lijing Zhu and Xia Wang and Xiaohong Xu and Wenjun Cheng and Jie Tang and Qi-Zhou Zhu and Xiaojun Chen and Ruifang An and Jun Gao and Guiling Li and Zhiye Zhang and Hui Zhou and Qi Zhou},
  title = {{IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.}},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.2025.43.16\_suppl.5565},
}

Loading related content...

Figure